Article
LncRNA MDRL Mitigates Atherosclerosis through miR-361/SQSTM1/NLRP3 Signaling
Mediators of Inflammation · 2022 · Ling You, author Yanjie Zheng, author Jing Yang, author Qian Hou, author Lianxia Wang, author Yan Zhang, author Chunxia Zhao, author Ruiqin Xie, author Amilia Aminuddin, Academic Editor
Key facts
| Title | LncRNA MDRL Mitigates Atherosclerosis through miR-361/SQSTM1/NLRP3 Signaling |
|---|---|
| First author | Ling You, author Yanjie Zheng, author Jing Yang, author Qian Hou, author Lianxia Wang, author Yan Zhang, author Chunxia Zhao, author Ruiqin Xie, author Amilia Aminuddin, Academic Editor |
| Journal | Mediators of Inflammation |
| Published | Apr 18, 2022 |
| DOI | 10.1155/2022/5463505 |
| Devices mentioned | K042152, K870938, K940422, K982100 |
| Product codes mentioned | CFN, DFZ, KIS, MVU |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1